Structural insights into the RNA binding inhibitors of the C-terminal domain of the SARS-CoV-2 nucleocapsid
Journal of Structural Biology · 2025-06 · 217 (2) · 108197
DOI: 10.1016/j.jsb.2025.108197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Structural Biology, 2025-06. Verfasst von Preeti Dhaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand 247667, India. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus Nucleocapsid Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: Government of India Department of Biotechnology, Department of Science and Technology, Ministry of Science and Technology, India, Indian Institute of Technology Roorkee.
Abstract (Originalsprache)
The SARS-CoV-2 nucleocapsid (N) protein is an essential structural element of the virion, playing a crucial role in enclosing the viral genome into a ribonucleoprotein (RNP) assembly, as well as viral replication and transmission. The C-terminal domain of the N-protein (N-CTD) is essential for encapsidation, contributing to the stabilization of the RNP complex. In a previous study, three inhibitors (ceftriaxone, cefuroxime, and ampicillin) were screened for their potential to disrupt the RNA packaging process by targeting the N-protein. However, the binding efficacy, mechanism of RNA binding inhibition, and molecular insights of binding with N-CTD remain unclear. In this study, we evaluated the binding efficacy of these inhibitors using isothermal titration calorimetry (ITC), revealing the affinity of ceftriaxone (18 ± 1.3 μM), cefuroxime (55 ± 4.2 μM), and ampicillin (28 ± 1.2 μM) with the N-CTD. Further inhibition assay and fluorescence polarisation assay demonstrated RNA binding inhibition, with IC50 ranging from ∼ 12 to 18 μM and KD values between 24 μM to 32 μM for the inhibitors, respectively. Additionally, we also determined the inhibitor-bound complex crystal structures of N-CTD-Ceftriaxone (2.0 Å) and N-CTD-Ampicillin (2.2 Å), along with the structure of apo N-CTD (1.4 Å). These crystal structures revealed previously unobserved interaction sites involving residues K261, K266, R293, Q294, and W301 at the oligomerization interface and the predicted RNA-binding region of N-CTD. These findings provide valuable molecular insights into the inhibition of N-CTD, highlighting its potential as an underexplored but promising target for the development of novel antiviral agents against coronaviruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand 247667, India.
- Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand 247667, India. Electronic address: pravindra.kumar@bt.iitr.ac.in.
- Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand 247667, India. Electronic address: shailly.tomar@bt.iitr.ac.in.
Förderung
- Government of India Department of Biotechnology
- Department of Science and Technology, Ministry of Science and Technology, India
- Indian Institute of Technology Roorkee
- Ministry of Education, India
- Science and Engineering Research Board
Zitieren
APA
Dhaka, P., Mahto, J. K., Singh, A., Kumar, P., & Tomar, S. (2025). Structural insights into the RNA binding inhibitors of the C-terminal domain of the SARS-CoV-2 nucleocapsid. Journal of Structural Biology, 217(2), 108197. https://doi.org/10.1016/j.jsb.2025.108197
Vancouver
Dhaka P, Mahto JK, Singh A, Kumar P, Tomar S. Structural insights into the RNA binding inhibitors of the C-terminal domain of the SARS-CoV-2 nucleocapsid. Journal of Structural Biology. 2025;217(2):108197. doi:10.1016/j.jsb.2025.108197
BibTeX
@article{Dhaka2025,
author = {Dhaka, Preeti and Mahto, Jai Krishna and Singh, Ankur and Kumar, Pravindra and Tomar, Shailly},
title = {Structural insights into the RNA binding inhibitors of the C-terminal domain of the SARS-CoV-2 nucleocapsid},
journal = {Journal of Structural Biology},
year = {2025},
volume = {217},
number = {2},
pages = {108197},
doi = {10.1016/j.jsb.2025.108197}
}
EUVIMED